Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant ...

Transgene and NEC will present promising new data from the ongoing randomized Phase I trial of the neoantigen individualized therapeutic cancer vaccine, TG4050 at SITC 2024 on November 9, 2024 (see ...

Roche’s Genentech is ending a partnership with Nykode Therapeutics that centered around a clinical-stage cancer vaccine ...

Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, today announced new findings related to its ...

PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free ...

While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...

When MRNA reports third-quarter earnings, investors will likely focus on the sales performance of its recently approved RSV ...

Moderna, Inc. MRNA reported earnings of 3 cents per share in the third quarter of 2024. The Zacks Consensus Estimate was a ...

At Circio, we are developing a protein-based polyvalent KRAS neoantigen vaccine that can induce robust KRAS-specific T-cell responses in the clinic as an off-the-shelf therapeutic cancer vaccine.” ...

In the final episode, experts at UCSD and La Jolla Institute discuss current clinical trials of a cancer vaccine and future directions for neoantigen vaccines. Custom-made Cancer Therapy ...